首页> 外文会议>International Conference on Physics of Cancer >6.3 MeV Fast Neutrons in the Treatment of Patients with Locally Advanced and Locally Recurrent Breast Cancer

【24h】

6.3 MeV Fast Neutrons in the Treatment of Patients with Locally Advanced and Locally Recurrent Breast Cancer

机译：6.3 MeV快速中子治疗局部晚期和局部复发性乳腺癌的患者

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

The study included 135 breast cancer patients (70 patients with locally recurrent breast cancer and 65 patients with locally advanced breast cancer with unfavorable prognostic factors) who received the neutron therapy alone or in combination with the photon therapy. The neutron therapy was shown to be effective in multimodality treatment of patients with locally advanced and locally recurrent breast cancer. The 8-year survival rate in patients without repeated breast cancer recurrence was 87.6 ± 8.7% after the neutron and neutron-photon therapy and 54.3 ± 9.2% after the electron beam therapy.

机译：该研究包括135名乳腺癌患者（70例局部复发性乳腺癌和65名患有局部晚期乳腺癌的患者，具有不利的预后因素），他们仅接受单独的中子治疗或与光子疗法结合。显示中子疗法在局部晚期和局部复发性乳腺癌的患者的多模态治疗方面是有效的。在中子和中子光子疗法后，没有重复乳腺癌复发的患者的8年生存率为87.6±8.7％，电子束疗法后54.3±9.2％。

著录项

来源
《International Conference on Physics of Cancer》|2016年|various paging|共4页
会议地点
作者
V. V. Velikaya; L. I. Musabaeva; V. A. Lisin; Zh. A. Startseva;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：国际，第3阶段试验：Balixafortide（CXCR4拮抗剂）加二林蛋白与Eribulin单独服用Her2阴性，局部复发或转移性乳腺癌（堡垒）国际，第3阶段试验：Balixafortide（A CXCR4拮抗剂）加二林蛋白与二林林单独相反 HER2阴性，局部复发或转移性乳腺癌（堡垒）的患者
2. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer [J] . Lu Dan, Li Chunze, Riggs Matthew, Cancer chemotherapy and pharmacology. . 2019,第1期

机译：Trastuzumab Emtansine（T-DM1）的药代动力学作为单一的药剂，或者与患有复发或局部晚期转移性乳腺癌的HER2阳性乳腺癌患者中的Pertuzumab
3. Fast Neutron Therapy (FNT) for locally recurrent breast cancer: Acute and late toxicity [J] . Neff T., Specht H. M., Petry W., Strahlentherapie und Onkologie . 2016,第Suppla1期

机译：局部复发性乳腺癌的快速中子疗法（FNT）：急性和晚期毒性
4. 6.3 MeV Fast Neutrons in the Treatment of Patients with Locally Advanced and Locally Recurrent Breast Cancer [C] . V. V. Velikaya, L. I. Musabaeva, V. A. Lisin, International Conference on Physics of Cancer . 2016

机译：6.3 MeV快速中子治疗局部晚期和局部复发性乳腺癌的患者
5. Diffusion-weighted magnetic resonance imaging in monitoring treatment response in patients with locally advanced breast cancer. [D] . Singer, Lisa. 2010

机译：扩散加权磁共振成像可监测局部晚期乳腺癌患者的治疗反应。
6. Phase II study on paclitaxel in patients with recurrent metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group) [O] . P. O. Witteveen, J. van der Velden, I. Vergote, -1

机译：紫杉醇在不适合手术或放疗的复发性转移性或局部晚期外阴癌患者中进行的紫杉醇II期研究：EORTC-GCG（欧洲癌症研究与治疗组织-妇科癌症研究组）的研究
7. 6.3 MeV fast neutrons in the treatment of patients with locally advanced and locally recurrent breast cancer [O] . Velikaya, V. V., Musabaeva, L. I., Lisin, V. A., 2016

机译：6.3 MeV快速中子治疗局部晚期和局部复发性乳腺癌患者
8. P53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer [R] . Carey, L. A. , Dorsey, K. C. , Dressler, L. , 2006

机译：p53突变分析预测局部晚期乳腺癌新辅助治疗患者的肿瘤反应

6.3 MeV Fast Neutrons in the Treatment of Patients with Locally Advanced and Locally Recurrent Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅